Caficrestat
As of the edition of 20 October 2026, Caficrestat is a small molecule: in active development; acts on AKR1B1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Infections; Inherited and neonatal; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AKR1B1 | Aldo-keto reductase family 1 member B1 | P15121 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Alltech Life Sciences | Lead sponsor of trials | 2012 to now |
| Cycle Pharmaceuticals | Lead sponsor of trials | 2019 to now |
| Arctic Therapeutics | Lead sponsor of trials | 2024 to now |